Recent News

• 11.25.2025 - Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762
• 11.17.2025 - Phio Pharmaceuticals Announces Upcoming Podium Presentation at the Advanced Therapies USA 2025 Congress
• 11.13.2025 - Phio Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
• 11.07.2025 - Phio Pharmaceuticals to Present Recent Clinical Results from Skin Cancer Trial with siRNA based INTASYL PH-762
• 11.07.2025 - Phio Pharmaceuticals Announces INTASYL PH-762 is Named Immunomodulatory Solution of the Year in the BioTech Breakthrough Award Program
• 11.03.2025 - Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $13.4 Million Gross Proceeds

Recent Filings

• 11.24.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.24.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.20.2025 - S-3 Registration statement under Securities Act of 1933
• 11.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.13.2025 - EX-99.1 EX-99.1
• 11.13.2025 - 8-K Current report
• 11.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.12.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.12.2025 - D Notice of Exempt Offering of Securities
• 11.10.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors